Insider · CIK 0001661887
Nicholas Grund
Files at AKBA (Akebia Therapeutics, Inc.). First filing Feb 4, 2025, latest Feb 4, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKBA: Akebia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Akebia Therapeutics, Inc. | $118k 84,829 shares | -13% | +3% from low-66% from high | |
| 25Weak | Akebia Therapeutics, Inc. | $117k 55,621 shares | -11% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -53,585 | $1.39 | $74k | 592,994 | Feb 4, 2026 |
| Feb 2, 2026 | AKBA Akebia Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -31,244 | $1.39 | $43k | 561,750 | Feb 4, 2026 |
| Jan 30, 2026 | AKBA Akebia Therapeutics, Inc. | AGrant or award Common Stock | +204,000 | $0.00 | $0 | 646,579 | Feb 3, 2026 |
| Jan 30, 2026 | AKBA Akebia Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +320,000 | $0.00 | $0 | 320,000 | Feb 3, 2026 |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +194,900 | $0.00 | $0 | 498,200 | Feb 4, 2025 |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -55,621 | $2.10 | $117k | 442,579 | Feb 4, 2025 |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.